Atreca, Inc. (NASDAQ:BCEL) Expected to Post Earnings of -$0.70 Per Share

Wall Street analysts expect that Atreca, Inc. (NASDAQ:BCEL – Get Rating) will report ($0.70) earnings per share (EPS) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Atreca’s earnings, with the lowest EPS estimate coming in at ($0.80) and the highest estimate coming in at ($0.66). Atreca posted earnings per share of ($0.72) in the same quarter last year, which indicates a positive year over year growth rate of 2.8%. The company is expected to issue its next quarterly earnings results on Monday, January 1st.

On average, analysts expect that Atreca will report full-year earnings of ($2.74) per share for the current year, with EPS estimates ranging from ($2.93) to ($2.48). For the next fiscal year, analysts anticipate that the company will post earnings of ($2.54) per share, with EPS estimates ranging from ($3.37) to ($2.16). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side research analysts that cover Atreca.

Atreca (NASDAQ:BCEL – Get Rating) last announced its quarterly earnings results on Wednesday, May 11th. The company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.13.

Several brokerages have commented on BCEL. Zacks Investment Research lowered shares of Atreca from a “hold” rating to a “sell” rating in a research note on Monday, May 9th. Wedbush restated an “outperform” rating on shares of Atreca in a research note on Friday, March 4th. Robert W. Baird dropped their price target on shares of Atreca from $12.00 to $9.00 in a research note on Thursday. HC Wainwright restated a “buy” rating and issued a $25.00 price target on shares of Atreca in a research note on Wednesday, April 6th. Finally, Stifel Nicolaus lowered their price objective on shares of Atreca from $17.00 to $14.00 and set a “buy” rating on the stock in a research note on Friday, March 4th. One analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. According to MarketBeat, Atreca currently has an average rating of “Buy” and a consensus price target of $15.38.

BCEL opened at $1.69 on Friday. The firm has a market cap of $63.81 million, a price-to-earnings ratio of -0.58 and a beta of 0.78. Atreca has a fifty-two week low of $1.56 and a fifty-two week high of $10.73. The company’s 50-day moving average price is $2.61 and its 200 day moving average price is $2.93.

In related news, insider Tito Serafini sold 30,000 shares of the firm’s stock in a transaction that occurred on Friday, March 4th. The shares were sold at an average price of $5.00, for a total value of $150,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 7.68% of the company’s stock.

A number of hedge funds have recently added to or reduced their stakes in BCEL. BNP Paribas Arbitrage SA lifted its position in Atreca by 62.8% in the 3rd quarter. BNP Paribas Arbitrage SA now owns 5,186 shares of the company’s stock worth $32,000 after buying an additional 2,000 shares in the last quarter. Virtu Financial LLC bought a new position in shares of Atreca during the 4th quarter valued at $40,000. Dynamic Technology Lab Private Ltd bought a new position in shares of Atreca during the 1st quarter valued at $41,000. IHT Wealth Management LLC bought a new position in shares of Atreca during the 1st quarter valued at $41,000. Finally, McDonald Partners LLC bought a new position in shares of Atreca during the 1st quarter valued at $42,000. Institutional investors own 57.48% of the company’s stock.

Atreca Company Profile (Get Rating)

Atreca, Inc, a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform.

Read More